Psoriasis and psoriatic arthritis: Clinical features and disease mechanisms

被引:94
作者
Myers, Wendy A. [1 ]
Gottlieb, Alice B.
Mease, Philip
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Psoriasis Ctr Excellence, New Brunswick, NJ 08903 USA
[2] Tufts Univ, Sch Med, Tufts New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA
[3] Univ Washington, Sch Med, Swedish Hosp Med Ctr, Seattle Rheumatol Associates, Seattle, WA 98104 USA
关键词
D O I
10.1016/j.clindermatol.2006.07.006
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is a chronic skin disorder affecting approximately 1% to 3% of the world's population. A considerable proportion of patients with psoriasis will develop a form of inflammatory arthritis known as psoriatic arthritis whose prevalence is poorly defined. Significant advances have been made in determining the pathophysiology of both of these diseases, with recent findings strongly implicating T cells and inflammatory cytokines such as tumor necrosis factor a in their pathogenesis. There exists an increasing array of therapies to benefit both skin and musculoskeletal manifestations. Newer therapies, such as the biologics, are providing more targeted approaches with potentially fewer systemic toxicities, providing control of disease symptoms and inhibiting progressive joint damage in those with arthritis, as well as improving long-term function and quality of life. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:438 / 447
页数:10
相关论文
共 62 条
  • [1] Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
    Antoni, C
    Krueger, GG
    de Vlam, K
    Birbara, C
    Beutler, A
    Guzzo, C
    Zhou, B
    Dooley, LT
    Kavanaugh, A
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) : 1150 - 1157
  • [2] Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
    Antoni, CE
    Kavanagh, A
    Kirkham, B
    Tutuncu, Z
    Burmester, GR
    Schneider, U
    Furst, DE
    Molitor, J
    Keystone, E
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, DJ
    Weisman, MH
    Kalden, JR
    Smolen, J
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (04): : 1227 - 1236
  • [3] Appel H, 2005, ANN RHEUM DIS, V64, P108
  • [4] Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy
    Baeten, D
    Kruithof, E
    De Rycke, L
    Boots, AM
    Mielants, H
    Veys, EM
    De Keyser, F
    [J]. ARTHRITIS RESEARCH & THERAPY, 2005, 7 (02) : R359 - R369
  • [5] Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis
    Chamian, F
    Krueger, JG
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (04) : 331 - 337
  • [6] Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis - A Department of Veterans Affairs cooperative study
    Clegg, DO
    Reda, DJ
    Mejias, E
    Cannon, GW
    Weisman, MH
    Taylor, T
    BudimanMak, E
    Blackburn, WD
    Vasey, FB
    Mahowald, ML
    Cush, JJ
    Schumacher, HR
    Silverman, SL
    Alepa, FP
    Luggen, ME
    Cohen, MR
    Makkena, R
    Haakenson, CM
    Ward, RH
    Manaster, BJ
    Anderson, RJ
    Ward, JR
    Henderson, WG
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (12): : 2013 - 2020
  • [7] Alefacept, an immunomodulatory recombinant FA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells
    da Silva, AJ
    Brickelmaier, M
    Majeau, GR
    Li, ZF
    Su, LH
    Hsu, YM
    Hochman, PS
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (09) : 4462 - 4471
  • [8] de Rie Menno A, 2004, Dermatol Ther, V17, P341, DOI 10.1111/j.1396-0296.2004.04037.x
  • [9] Elder JT, 2001, ARCH DERMATOL, V137, P1447
  • [10] Psoriasis of early and late onset:: A clinical and epidemiologic study from Spain
    Ferrándiz, C
    Pujol, RM
    García-Patos, V
    Bordas, X
    Smandía, JA
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (06) : 867 - 873